Interview with Ronald Christie, VP Interntaional Operations – General…
We found a Capital Markets Day presentation from Novo Nordisk that talked about the “rule of halves” – that of all people with diabetes, 50% of diagnosed, and of those…
Address: East Third Ring Road, Chaoyang District, Beijing No. 1 World Financial Center, East Building 18 Zip Code: 100020
Tel: +86 (010) 59615858
Web: http://www.novonordisk.com.cn/documents/home_page/document/index.asp
Novo Nordisk’s products were introduced to the Chinese market as early as the 1960s. In 1994 Novo Nordisk decided to invest in China by setting up Novo Nordisk (Tianjin) Biotechnology Co., Ltd., which was later renamed Novo Nordisk (China) Pharmaceuticals Co., Ltd.
Headquartered in Beijing, Novo Nordisk now employs more than 1,700 employees and has:
• regional offices in Shanghai, Guangzhou, Wuhan, Shenyang, Jinan and Hong Kong,
• production facilities in Tianjin
• a R&D center in Beijing.
Step by step, Novo Nordisk has become the leader in diabetes in China, with a complete organization covering R&D, production, sales and distribution networks.
While providing all major diabetes treatment products and comprehensive diabetes care to people with diabetes in China, Novo Nordisk is also committed to China’s environment and society and has launched social programs such as for example the NovoCare Bus, the NovoCare Club and the “NovoCare Sunshine Program” in Xinjiang, which is an insulin donation program in an earthquake-ravaged area.
R & D, diabetes treatment products, haemostasis management, hormone replacement therapy
We found a Capital Markets Day presentation from Novo Nordisk that talked about the “rule of halves” – that of all people with diabetes, 50% of diagnosed, and of those…
Transcenta’s Xueming Qian outlines the new company’s origins, the space it seeks to fill within the highly competitive Chinese oncology market, and where Chinese biotech stands globally in 2019. …
Boehringer Ingelheim veteran executive Felix Gutsche shares the first impressions of the China market since he joined in January 2019; the strategic significance of the market as one of the…
Multinational pharma companies have been setting up shop in China ever since Novartis launched its Chinese affiliate in 1987, with other pharma giants following in its footsteps soon after, eager…
Gaobo Zhou is Partner and co-leader of the Healthcare Practice in China and has been with McKinsey for over a decade, Gaobo discusses the changes occurring within the complex and…
“Mental health is currently a major problem in China, and will become an ever greater problem unless effective interventions are put in place.” Mental Health has Long Been a…
Pius Hornstein, Country Chair of Sanofi China appointed in March 2019, shares his initial impressions on the fast-changing Chinese market; his mandate to drive a transformation of the organization in…
HE Ming, founder and CEO of Sino-American (Suzhou) Pharmaceutical Services (SAPS), shares his commitment to bringing international quality standards to the Chinese pharma industry, the comprehensive portfolio of quality management,…
Dr Shuqian Jing, founder, Chairman and CEO of Gmax Biopharm, an innovative biotech company headquartered in Hangzhou, shares how his experiences at global biopharma companies like BMS and Amgen inspired…
Serial entrepreneur and Ronnsi CEO Yiming Yao discusses the inspiration behind the company’s formation, its unique specialization in ovine heparin, and his strategy to take the firm to the next…
China’s rapidly-growing biotech sector is increasingly hungry for preclinical drug candidates to commercialise in China, and Chinese companies are spending top dollar for cutting-edge technology from the US and UK.…
Dr Dafang Zhong, director of Shanghai Center for Drug Metabolism and Pharmacokinetics Research at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, shares his professional career within the…
Eurasia Group’s Aditya Bhattacharji looks at the potentially damaging fallout of the ongoing US-China trade war on the life sciences industry. Biotech [is the] new frontier for US-China tensions…
See our Cookie Privacy Policy Here
